Efficacy of Intra-Articular Bevacizumab in Preventing Recurrent Hemarthrosis in Hemophilia Patients With Chronic Synovitis: A Pre- and Post-Design Study

What this Trial Is About

This research aims to evaluate the use of intra-articular Bevacizumab, a monoclonal antibody that blocks Vascular Endothelial Growth Factor (VEGF), to prevent recurrent joint bleeding in patients with Hemophilia A who have chronic synovitis. Hemophilia is a genetic bleeding disorder that often causes repeated bleeding into joints, leading to chronic inflammation and joint damage. This trial seeks to reduce these bleeding episodes and slow joint deterioration by targeting the underlying VEGF-driven process. Participants will receive monthly injections of Bevacizumab directly into affected joints (knee, elbow, or ankle) following preventive factor replacement therapy to avoid bleeding complications. The first four patients will receive 20 mg doses, and if well tolerated, subsequent participants will receive 40 mg doses. Each patient will receive a total of four injections over four months. This open-label, single-arm study will be conducted over two years and involves 25 participants. Throughout the study, researchers will monitor joint bleeding rates before and after treatment, assess joint health using a clinical scoring tool at multiple intervals up to one year, and evaluate joint inflammation and effusion through MRI scans before treatment and six months after completion. The study aims to provide insights into this targeted therapy's potential to improve long-term joint health in hemophilia patients while tracking safety and treatment effects over time.

Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis